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Abstract
Background:  Gene expression profiling of small numbers of cells requires high-fidelity
amplification of sub-nanogram amounts of RNA. Several methods for RNA amplification are
available; however, there has been little consideration of the accuracy of these methods when
working with very low-input quantities of RNA as is often required with rare clinical samples.
Starting with 250 picograms-3.3 nanograms of total RNA, we compared two linear amplification
methods 1) modified T7 and 2) Arcturus RiboAmp HS and a logarithmic amplification, 3) Balanced
PCR. Microarray data from each amplification method were validated against quantitative real-time
PCR (QPCR) for 37 genes.
Results: For high intensity spots, mean Pearson correlations were quite acceptable for both total
RNA and low-input quantities amplified with each of the 3 methods. Microarray filtering and data
processing has an important effect on the correlation coefficient results generated by each method.
Arrays derived from total RNA had higher Pearson's correlations than did arrays derived from
amplified RNA when considering the entire unprocessed dataset, however, when considering a
gene set of high signal intensity, the amplified arrays had superior correlation coefficients than did
the total RNA arrays.
Conclusion: Gene expression arrays can be obtained with sub-nanogram input of total RNA. High
intensity spots showed better correlation on array-array analysis than did unfiltered data, however,
QPCR validated the accuracy of gene expression array profiling from low-input quantities of RNA
with all 3 amplification techniques. RNA amplification and expression analysis at the sub-nanogram
input level is both feasible and accurate if data processing is used to focus attention to high intensity
genes for microarrays or if QPCR is used as a gold standard for validation.
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Background
Expression array analysis has provided valuable new
insights into the biology and pathophysiology of many
cancers [1-4]. However, initial studies required relatively
large amounts of tumor tissue (typically 4–40 ug of total
RNA). It is important to extend these powerful analytical
methods to much smaller quantities of cells, such as rare
clinical specimens, including small tumors, core biopsies,
or even individual cells. Working with limited amounts of
RNA does introduce problems related to signal versus
noise amplification[5]. This is relevant when considering
expression profiling of samples from needle biopsies, rare
tissue samples and pure cellular preparations and plan-
ning experimental design and data analysis.
Feasibility and reproducibility has been established for
linear amplification from nanogram to low microgram
input quantities of total RNA to yield high fidelity gene
amplification products suitable for gene expression
microarray analysis [6-16]. In an experimental model
using reverse transcribed product diluted down to the sub-
nanogram range, Subkhankulova et al were the first to
report comparisons of amplification techniques at the
sub-nanogram level[17]. They compared 1) T7 based lin-
ear amplification to 2) switching mechanism at 5'end of
RNA template (SMART) PCR and 3) global PCR amplifi-
cation[17]. Surprisingly, they found that PCR amplifica-
tion was more reliable than linear amplification for
detecting true expression differences between picogram
input samples with higher correlation between technical
replicates than linear amplification. Unfortunately, this
higher true-positive rate was at the expense of a consider-
ably decreased absolute discovery rate. In contrast, Wang
et al compared T7 based linear amplification to SMART
PCR and found that while both methods achieved repro-
ducible, reliable results that the T7 based method yielded
more amplified RNA and is therefore preferred when the
amount of starting total RNA is limited[18] We evaluated
the hypothesis that high fidelity amplification is possible
by both linear and PCR based methods when starting with
samples containing sub-nanogram amounts of total RNA.
Methods
To test our hypothesis, serial dilutions of stock RNA was
employed for a comparison of 3 amplification techniques
with assessment by technical replicates of microarrays and
with subsequent validation by QPCR of both total and
amplified RNA.
RNA Isolation
Total RNA was prepared from the BT474 cell line and
Stratagene Universal Human Reference RNA (StratRef)
(Stratagene, La Jolla, CA) using the Arcturus PicoPure
RNA isolation kit (Mountain View, CA) as per manufac-
turer's instructions. StratRef is composed of total RNA
from 10 human cell lines and is designed to be used as a
reference for microarray gene-profiling experiments.
Serial dilutions of StratRef and BT474 RNA served as the
substrate for all amplification reactions to minimize
sources of variability.
Total RNA labeling without amplification
10 μg of total RNA from the BT474 breast cancer cell line
and StratRef RNA was reverse transcribed using
Stratascript RT (Stratagene, La Jolla, CA) in the presence of
10 μg of random hexamer (Amersham Pharmacia) and
oligo d(T)24NN (sequence provided in table 1) using the
reverse transcriptase manufacturer's recommended proto-
col.
Modified T7 RNA amplification
Total RNA from the BT474 breast cancer cell line and
StratRef was linearly amplified through two rounds of in
vitro transcription (IVT) based on a modified T7 amplifi-
cation[19]. Reverse transcription (RT) of total RNA was
performed using 100 ng of oligo dT-T7 primer (sequence
provided in table 1) First strand synthesis was as described
previously[8], however, T4gp32 was added in the first
strand synthesis to improve full-length DNA synthe-
sis[20]. Second strand synthesis was performed followed
by DNA purification with Zymo DNA Clean and Concen-
trator kits (Zymo Research, Orange, CA). Two rounds of in
vitro transcription were performed[8]. Samples were puri-
fied with Qiagen RNeasy mini columns (Qiagen, Valencia
CA).
Arcturus HS amplification
Total RNA from the BT474 breast cancer cell line and
StratRef (Stratagene, La Jolla, CA), was linearly amplified
through two rounds of in vitro transcription according to
the manufacturer's published instructions (at the time of
these experiments reagents were produced by Arcturus,
Mountain View, CA, now MDS Analytical Technologies,
Sunnyvale, CA). Their protocol specified that a minimum
input of 100–500 picograms of total RNA are required for
successful amplification with this kit designed specifically
for low-input total RNA samples, which is equivalent to
10–50 cells. Per the manufacturer's specifications, 200 ng
of Poly dIdC nucleic acid carrier was added to each reac-
tion. IVT reaction time was 6.5 hours.
Balanced PCR amplification
Total RNA from the BT474 breast cancer cell line and
StratRef (Stratagene, La Jolla, CA), was reverse transcribed
using separate oligo dTT7 primers, pooled and exponen-
tially amplified in the same PCR tube[21]. Briefly, the bal-
anced PCR reactions were carried out as follows. We
mixed 1 μl of cDNA from the target cells or from the ref-
erence with T4 DNA ligase buffer, and restricted it with 0.5
μl of 10 U/μl NlaIII at 37°C for one hour. For digestionBMC Genomics 2009, 10:326 http://www.biomedcentral.com/1471-2164/10/326
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with NlaIII, linker LN1 is used for control and LN2 for tar-
get cDNA (sequence provided in Table 1). We annealed
the appropriate linkers to cDNA by serially decreasing the
temperature of the sample from 50°C to 10°C at 5°C
ramp in 5 minute steps. We then added 0.5 μl of 2,000 U/
μl T4 DNA ligase and incubated at room temperature for
1 hour. We then mixed together the cDNAs ligated to dif-
ferent linkers and purified the mixture with a QIAquick
PCR Purification Kit (Qiagen, Valencia CA).
To 20 μl of purified-ligated DNA, we used the Advantage
2 PCR Polymerase system as per manufacturer's instruc-
tions (Clontech, Mountain View CA), dNTP mix (10 mM
ea.), 1 μl of 10 μM common primer P1 (sequence pro-
vided in Table 1) and 22 μl of H2O. PCR was performed
at 72°C for 8 minutes; 95°C for 1 minute; 20 cycles of
95°C for 30 seconds and 72°C for 1 minutes; then 72°C
for 5 minutes. We purified the PCR product twice with
QIAquick PCR Purification Kit (Qiagen, Valencia CA) and
eluted the DNA in 50 μl of H2O. We quantified the cDNA
concentration with Picogreen (Invitrogen, Carlsbad CA).
We mixed 1 μl of 3 ng/μl DNA with 5 μl of 10× TITA-
NIUM™ Taq PCR Buffer (Clontech, Mountain View CA), 1
μl of 50× TITANIUM™ Taq Polymerase (Clontech, Moun-
tain View CA), 1 μl of 50× dNTP Mix (10 mM ea.), 5 μl of
4 μM P2a for LN1-ligated cDNA or P2b for LN2-ligated
cDNA, and 37 μl of H2O. We separated and amplified the
cDNA at 95°C for 1 minute; 10 cycles of 95°C for 30 sec-
onds and 72°C for 1 minute; and 72°C for 5 minutes.
Four reactions were carried out per sample and were
pooled.
Although the balanced PCR reactions were carried out in
a different laboratory (Makrigiorgos lab, Boston MA) than
the linear amplifications (Haqq lab, San Francisco, CA),
an aliquot of RNA from the same tube of StratRef RNA
and an aliquot of the same preparation of BT474 RNA as
was used to minimize input variability. Reverse transcrip-
tion of this RNA was performed before shipping the cDNA
on dry ice for the subsequent Balanced PCR reactions.
Coupling, array hybridization and analysis were all per-
formed in the Haqq lab, as were all other techniques
described.
Assessment of Transcript Integrity
The molecular weight profile and integrity of each ampli-
fied RNA/DNA species was evaluated using the Agilent
Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA)
with a RNA 6000 Pico Lab Chip.
Fluorescent labeling
1.25 μg of amplified RNAs (aRNAs) produced with Mod-
ified T7 and Arcturus RiboAmp HS were converted to
amino-allyl modified cDNA and coupled to N-hydroxy-
succinimidyl esters of Cy3 or Cy5 (Amersham, Piscata-
way, NJ)[22]. The Balanced PCR amplified cDNAs (1.25
μg) were labeled with Klenow from BioPrime (Invitrogen,
Carlsbad, CA) and Cy3/Cy5 dUTP (Amersham, Piscata-
Table 1: Lower limits of total RNA required for each amplification method.
Amplification technique Modified T7 Amplification yield, BT474 RNA(mcg)
140 pg 0.80 – insufficient
280 pg 0.60 – insufficient
375 pg 0.16 – insufficient
500 pg 1.4 – sufficient for 1 array
500 pg 1.7 – sufficient for 1 array
500 pg 0 – insufficient
500 pg 0 – insufficient
500 pg 1.9 – sufficient for 1 array
1 ng 17.8
1 ng 20.3
Arcturus
100 pg 0 – insufficient
100 pg 0 – insufficient
250 pg 12
250 pg 7.2
500 pg 56.8
1 ng 52.7
Balanced PCR*
500 pg 0 – insufficient
500 pg 1.5 – sufficient for 1 array
667 pg 2.1 – sufficient for 1 array
667 pg 2.0 – sufficient for 1 array
1 ng 0 – insufficient
1 ng 2.0 – sufficient for 1 array
3.3 ng 2.3 – sufficient for 1 array
3.3 ng 3.2
*1 array discarded due to poor hybridizationBMC Genomics 2009, 10:326 http://www.biomedcentral.com/1471-2164/10/326
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way, NJ). All specimens were then hybridized to a micro-
array slide at 65°C for 12–16 hours. The slide was then
washed and immediately scanned with Axon Imager
4000b (Axon Instruments, Union City, CA), utilizing
GenePixPro 3.0 software.
Microarrays
The 20,862 cDNAs used in these studies were from
Research Genetics (Huntsville, AL), now Invitrogen
(Carlsbad, CA). On the basis of Unigene build 166, these
clones represent 19,740 independent loci. Hybridization,
washing, scanning and primary data analysis was per-
formed as previously described[23,24]. A total of 17 tech-
nical replicate microarrays, including 3 unamplified, 5 T7
amplified, 4 Arcturus amplified and 5 balanced PCR
amplified arrays for BT474 versus StratRef were per-
formed. Background subtraction and computation of
ratios were carried out using GenePix 3.0 (Axon Instru-
ments, Sunnyvale, CA). Background subtraction was per-
formed by subtracting the median feature background
intensity from median feature pixel intensity at each
wavelength (635 nm for Cy5 and 532 nm for Cy3). The
background subtracted values were then used to calculate
the ratio of medians (Cy5/Cy3) which corresponds to the
raw ratio value for each gene.
Microarray Data analysis
Gene expression was analyzed with Cluster[25] using the
average linkage metric and displayed using Treeview[26].
Genepix median of ratio values from the experiment were
subjected to linear normalization in NOMAD[24], log-
transformed (base 2) and filtered for genes where data
were present in more than 90% of experiments. After lin-
ear normalization, log (base 2) transformation and hier-
archical clustering, the cluster dataset was imported into
the SAM software package. One class analysis was per-
formed to identify genes representative of StratRef and
genes representative of BT474 (with 2–4 fold differences
in expression). Data was censored if more than one data
value was flagged in each group to eliminate poor quality
array data. Delta was chosen to limit the output gene list
so that less than 1% predicted false positives would be
included. Pearson correlation coefficients comparing
microarray and QPCR gene expression measurements
were made in Excel (Microsoft, Redmond, WA). Global
Pearson correlation coefficients for microarrays were cal-
culated using the statistical software package
R:limma[27].
Quantitative RT-PCR
cDNA was made from total RNA for both BT474 and
StratRef, in 100-μL reactions using M-MLV reverse tran-
scriptase and random hexamers incubated at 25°C for 10
min then 48°C for 30 min. Expression of each gene was
analyzed using the 5' nuclease assay (real-time TaqMan
RT-PCR; [28])with the ABI PRISM 7700 instrument
(Applied Biosystems (ABI), Foster City, CA). QPCR was
performed in triplicate technical replicates. Probe
sequences and cycle conditions are available upon
request. Relative expression levels were calculated com-
pared to beta-glucuronidase as detailed previously
[29,30].
Statistical Analysis
The mean expression ratios for each of the 3 amplification
techniques and for the total RNA method were calculated
for each technique. Analysis A is defined as the 37 QPCR
genes, Analysis B, the high intensity dataset, is defined as
all genes that had a 635 Median Intensity OR a 532
Median Intensity > 1500. Analysis C, the unfiltered data-
set, is defined as all of the genes on the microarray that
had data present for 90% of the arrays. Sensitivity, specif-
icity and percentage correct were calculated for each
method in Analysis A using QPCR results as the gold
standard. All pairs of correlation coefficients for Analysis
B and C were used to perform intramethod and inter-
method comparisons of mean correlation coefficients for
all methods using expression results from microarrays of
unamplified RNA as the gold standard.
Results
Figure 1 demonstrates a schematic of our study design. To
validate our microarray results, we utilized quantitative
RT-PCR (QPCR) for a panel of 37 genes. Unlike prior
studies that used QPCR to validate expression of outliers
– genes predominantly expressed in one RNA sample ver-
sus another – we selected QPCR primers to measure genes
that are under-expressed, equivalent, or over-expressed in
BT474 relative to StratRef total (unamplified) RNA (see
Additional file 1 for graphical distribution of QPCR
expression). Half of the genes were selected based on
SAM[31] (Significance analysis of microarrays) analysis of
total RNA BT474 expression relative to StratRef (2–4 fold
under/over-expression) (Additional file 2 total RNA). The
other half was selected to include genes that did not have
a minimum of a 2-fold change in expression, which are
genes considered to have low levels of expression on
microarray analysis. Thus, our QPCR validation experi-
ments were designed to determine whether fidelity of
amplification was compromised without regard to the
amplitude of the ratio of gene expression between two
RNA samples. Our QPCR gene set covers a wide dynamic
range of gene expression (including genes with equivalent
expression in BT474 relative to StratRef) and was selected
before amplifications were performed (see Additional file
3 for delta delta CTs).
Lowest Input RNA Concentrations Required for 
Reproducible RNA Amplification
The lower limits of total RNA required for each method
were defined as the lowest RNA input amount where
amplification reactions consistently yielded sufficientBMC Genomics 2009, 10:326 http://www.biomedcentral.com/1471-2164/10/326
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product to permit analysis on cDNA microarrays and con-
firmatory functional assays. These were 500 pg for modi-
fied T7, 250 pg for Arcturus RiboAmp HS, and 500 pg for
balanced PCR (Table 1). All 3 techniques had some fail-
ures to amplify low-input RNA, with successful input
ranges depending on the technique tested. At or below the
threshold of 500 pg, the Arcturus RiboAmp HS amplifica-
tion method was more likely to produce a successful
expression profile and also provided enough material for
multiple hybridizations or other biological analyses.
Assessment of Transcript Length
The size of the amplified products ranged from 100–4400
bases for all attempted amplifications. For the modified
T7 method, after two rounds of amplification the product
measured a mean of 3400 bases on the Agilent Bioana-
lyzer PicoChip. For Arcturus RiboAmp HS, after two
rounds of linear amplification the product measured a
mean of 3372 bases on the Agilent Bioanalyzer PicoChip.
The Balanced PCR products were evaluated on a 1% Aga-
rose gel and measured over 3500 bases (data not shown).
Amplification reactions that did not yield the requisite
1.25 ug of RNA were considered unsuccessful; all success-
ful reactions were validated with the Agilent Bioanalyzer
and none required study exclusion on that basis.
Pairwise correlation coefficients of microarray data
The Pearson's correlations and standard deviations for
intra-method and inter-method comparisons for the high
intensity genes are shown in Table 2. This data represents
the 739 most intensely expressed genes, identified by a
635 Median Intensity or a 532 Median Intensity > 1500.
The Pearson's correlations and standard deviations for
intra-method and inter-method comparisons for the all
unselected genes are shown in Table 3. This represents
17,001 genes found to be present as data points in >90%
of the microarrays.
Table 4 shows a summary of the true and false calls, sen-
sitivity and specificity of each amplification technique
compared to the QPCR results. Table 5 presents a sum-
mary of the true and false calls, sensitivity and specificity
of each method for the 739 most highly expressed genes
using unamplified RNA as the gold standard. Table 6
shows a summary of the same results for the 17,001 genes,
again using unamplified RNA as the gold standard.
Validation of Microarray Data
QPCR of amplified RNA was correlated with the QPCR of
total RNA for all methods with R2 of 0.87 for modified T7,
R2 0.86 for Arcturus RiboAmp HS and R2 0.75 for bal-
anced PCR.
Study Design – BT474 and Stratagene Universal Human Pooled Reference RNA were used as the substrate for these experi- ments Figure 1
Study Design – BT474 and Stratagene Universal Human Pooled Reference RNA were used as the substrate for 
these experiments. 10 ug of total RNA from each were hybridized to microarrays and labeled "total RNA arrays". SAM anal-
ysis from these total RNA arrays were used to select QPCR genes in an unbiased fashion prior to performing any amplification 
reaction. Total RNA was serially diluted, amplified, and hybridized to cDNA microarrays. QPCR was performed on total RNA 
and amplified RNA. Statistical analyses included microarray vs microarray analysis as well as microarray vs QPCR analysis.
BT474 and StratRef 
aliquots
Total RNA arrays
With 10 ug input
+ SAM of Total RNA arrays 
(used for selecting QPCR probes)
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3 amplification
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Table 2: The Pearson's correlations and standard deviations for intra-method and inter-method comparisons for 739 high intensity genes.
Unamp A Unamp 
A
Unamp B 0.78 Unam p 
B
Unamp C 0.78 0.90 Unamp 
C
Mod T7 D 0.72 0.79 0.78 Mod T7 
D*
Mod T7 E 0.72 0.80 0.77 0.89 Mod T7 
E
Mod T7 F 0.73 0.77 0.76 0.90 0.87 Mod T7 
F
Mod T7 G 0.73 0.77 0.76 0.90 0.86 0.94 Mod T7 
G
Mod T7 H 0.74 0.81 0.79 0.91 0.87 0.94 0.96 Mod T7 
H
Mod T7 I 0.78 0.80 0.79 0.90 0.86 0.94 0.95 0.95 Mod T7 
I
Arcturus J 0.71 0.78 0.77 0.89 0.87 0.89 0.91 0.92 0.90 Arcturus 
J
Arcturus K 0.72 0.80 0.77 0.88 0.87 0.86 0.86 0.88 0.86 0.89 Arcturus 
K
Arcturus L 0.73 0.79 0.79 0.88 0.85 0.86 0.88 0.89 0.88 0.88 0.86 Arcturus 
L
Arcturus M 0.74 0.82 0.80 0.92 0.88 0.88 0.90 0.92 0.89 0.90 0.91 0.93 Arcturus 
M
Bal PCR N 0.72 0.78 0.77 0.85 0.82 0.82 0.83 0.84 0.84 0.82 0.81 0.84 0.86 Bal PCR 
N
Bal PCR O 0.71 0.77 0.75 0.85 0.82 0.80 0.80 0.82 0.82 0.80 0.81 0.82 0.85 0.93 Bal PCR 
O
Bal PCR P 0.66 0.74 0.72 0.83 0.79 0.77 0.78 0.79 0.79 0.76 0.78 0.79 0.83 0.87 0.86 Bal PCR 
P
Bal PCR Q 0.68 0.73 0.72 0.81 0.78 0.76 0.77 0.78 0.78 0.76 0.77 0.80 0.82 0.89 0.90 0.85 Bal PCR 
Q
Intramethod Intermethod Mean R2
Mean 
R2
SD Range Unamp SD Mod T7 SD Arcturus SD Bal PCR SD
Unamp 0.82 0.06 0.78–
0.90
0.77 0.03 0.77 0.03 0.73 0.03
Mod T7 0.91 0.03 0.86–
0.96
0.77 0.03 0.88 0.02 0.81 0.03
Arcturus 0.90 0.02 0.86–
0.93
0.77 0.03 0.88 0.02 0.81 0.03
Bal PCR 0.88 0.03 0.82–
0.93
0.73 0.03 0.81 0.03 0.81 0.03B
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Table 3: The Pearson's correlations and standard deviations for intra-method and inter-method comparisons for the unfiltered gene set (17,001 genes).
Unamp A Unamp 
A
Unamp B 0.59 Unamp 
B
Unamp C 0.56 0.73 Unam p 
C
Mod T7 D 0.36 0.30 0.30 Mod T7 
D*
Mod T7 E 0.25 0.17 0.14 0.46 Mod T7 
E
Mod T7 F 0.36 0.30 0.29 0.60 0.41 Mod T7 
F
Mod T7 G 0.37 0.30 0.28 0.60 0.40 0.65 Mod T7 
G
Mod T7 H 0.30 0.21 0.21 0.50 0.37 0.51 0.54 Mod T7 
H
Mod T7 I 0.38 0.32 0.28 0.58 0.38 0.63 0.66 0.50 Mod T7 
I
Arcturus J 0.32 0.30 0.26 0.60 0.40 0.57 0.58 0.46 0.60 Arcturus 
J
Arcturus K 0.30 0.24 0.21 0.52 0.37 0.48 0.47 0.40 0.48 0.56 Arcturus 
K
Arcturus L 0.24 0.16 0.14 0.39 0.33 0.40 0.39 0.35 0.37 0.40 0.38 Arcturus 
L
Arcturus M 0.36 0.27 0.26 0.67 0.46 0.60 0.60 0.50 0.57 0.61 0.57 0.49 Arcturus 
M
Bal PCR N 0.29 0.20 0.19 0.42 0.29 0.35 0.37 0.31 0.38 0.37 0.37 0.41 0.36 Bal PCR 
N
Bal PCR O 0.27 0.18 0.17 0.37 0.26 0.30 0.30 0.30 0.31 0.30 0.29 0.28 0.38 0.49 Bal PCR 
O
Bal PCR P 0.33 0.25 0.22 0.48 0.31 0.39 0.38 0.34 0.38 0.36 0.39 0.34 0.50 0.56 0.49 Bal PCR 
P
Bal PCR Q 0.25 0.11 0.10 0.36 0.27 0.27 0.28 0.28 0.27 0.27 0.29 0.31 0.40 0.49 0.50 0.53
Intramethod Intermethod Mean R2
Mean R2 SD Range Unamp SD Mod T7 SD Arcturus SD Bal PCR SD
Unamp 0.63 0.07 0.56–0.73 0.28 0.07 0. 26 0.06 0.21 0.07
Mod T7 0.52 0.10 0.14–0.66 0.28 0.07 0.48 0.10 0.33 0.05
Arcturus 0.50 0.09 0.14–0.61 0.26 0.06 0.48 0.10 0.35 0.06
Bal PCR 0.51 0.03 0.10–0.56 0.21 0.07 0.33 0.05 0.35 0.06BMC Genomics 2009, 10:326 http://www.biomedcentral.com/1471-2164/10/326
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When dealing with clinical samples, microarray results are
often validated with QPCR; therefore techniques that
demonstrate a low false expression result (FER) by this
type of analysis are very desirable. We defined a FER as
number of discordant values divided by number of genes
analyzed for expression ratio by microarray compared to
QPCR using unamplified total RNA. Both array and QPCR
measurements were normalized to levels of β-glucuroni-
dase. As shown in Table 7, Balanced PCR showed a mean
percent FER of 11.3%, Arcturus RiboAmp HS showed
13.5%, and modified T7 showed 14.6%. The FER rates for
each method were independent of input RNA level by
ANOVA (p = 0.39).
When we compared QPCR of amplified to total RNA for
each method (in an effort to control for the potential bias
of each individual array hybridization), the FER was 0%
(0/21 genes) for Arcturus, 4.5% (1/22 genes) for modified
T7 and 15% (3/19 genes) for Balanced PCR.
Discussion
Not surprisingly, the unfiltered arrays showed poorer
overall correlation even between replicate arrays than did
the analysis filtered for high intensity spots. Even the
unamplified arrays had correlation coefficients somewhat
lower than expected when array data was unfiltered, indi-
cating that the filtration process removes the effect of
background and nonspecific hybridization on the cDNA
arrays. The filtration process did not change the individual
expression ratios but rather focused the analysis on genes
in which the hybridization gave a particularly strong sig-
nal, a strategy that seems logical when attempting to work
with very rare clinical specimens to ensure a lower false
call rate. Other groups have reported analysis of total RNA
arrays with input as high as 20–40 ug per microarray,
which may have improved the results for our total RNA
arrays[32] That being said, in real world situations
researchers will not have abundant amounts of clinically
relevant total RNA to use for comparisons to low-input
RNA samples. Confirmation of array results will require
Table 4: Statistical analysis of microarray versus QPCR results (37 genes)
Total
10 ug
Baugh
500 pg
Baugh
 1 ng
Baugh
10 ng
Arcturus
250 pg
Arcturus
500 pg
Arcturus
1 ng
BalPCR
0.667 ng
BalPCR
3.33 ng
True 
Positives
18 14 13 14 15 16 15 18 17
False 
Positives
311211023
True 
Negatives
15 17 17 16 17 17 18 16 15
False 
Negatives
156543412
Sensitivity 94.74% 73.68% 68.42% 73.68% 78.95% 84.21% 78.95% 94.74% 89.47%
Specificity 83.33% 94.44% 94.44% 88.89% 94.44% 94.44% 100.00% 88.89% 83.33%
T o t a l 3 73 73 73 73 73 73 73 73 7
% Correct 89.2% 83.8% 81.1% 81.1% 86.5% 89.2% 89.2% 91.9% 86.5%
Table 5: Statistical analysis of high intensity gene set (739 genes)
Baugh
500 pg
Baugh
1 ng
Baugh
10 ng
Arcturus
250 pg
Arcturus
500 pg
Arcturus
1 ng
BalPCR
0.667 ng
BalPCR
3.33 ng
True 
Positives
210 187 197 246 188 216 172 187
False 
Positives
150 95 127 274 123 161 93 144
True 
Negatives
332 387 304 208 328 319 389 338
False 
Negatives
47 70 48 11 58 41 85 70
Sensitivity 81.7% 72.8% 80.4% 95.7% 76.4% 84.0% 66.9% 72.8%
Specificity 68.9% 80.3% 70.5% 43.2% 72.7% 66.5% 80.7% 70.1%
Blanks 0 0 6 30 4 2200
Total 739 739 739 739 739 739 739 739
% Correct 73.3% 77.7% 67.8% 61.4% 69.8% 72.4% 75.9% 71.0%BMC Genomics 2009, 10:326 http://www.biomedcentral.com/1471-2164/10/326
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reliance on functional assays such as QPCR to validate
results, which is why we emphasized the QPCR compo-
nent of our analysis. All three methods tested showed
comparable accuracy rates that were within the range of
previous reports based on amplification from picogram
amounts of total RNA[17]. However, our study also deter-
mined the minimal input requirements of each of the 3
amplification methods. Table 1 shows the threshold for
each technique – for example, above 250 pg, the Arcturus
method worked reproducibly, while the modified T7 and
balanced PCR techniques required approximately 1 ng of
total RNA.
RNA amplification technologies serve translational clini-
cal research well. Linear amplification already has enabled
examination of gene expression in clinical core needle
biopsies[1], surgical biopsies[33], fine needle aspi-
rates[34] and even single human cells[35]. Our analysis of
the high intensity spots demonstrates that amplification is
reproducible and highly correlated with QPCR measure-
ments using sub-nanogram input RNA samples. These
results clearly demonstrate that data-processing has a
marked impact on expression array results, particularly
when working with very low-input samples.
While each method was able to provide data in the sub-
nanogram range, certain methods are advantageous over
others in terms of lower limit of RNA that can reliably be
amplified, cost per reaction and the number of days
required for processing of samples. The Arcturus Ribo-
Amp HS method was more reliable at generating expres-
sion arrays at the threshold of below a nanogram of total
RNA. For modified T7 and balanced PCR, a nanogram of
total RNA will ensure reliability. The Arcturus amplifica-
tion procedure was able to produce very substantial
amounts of nucleic acids from just 250 pg of total RNA
and therefore should be considered more reliable than the
other two methods at lower input thresholds. Caretti et al.
performed a comparison of amplifications of a colon
biopsy subjected to laser capture microdissection with
purification of an estimated 1 nanogram of RNA per spec-
imen; they compared the two cycle Arcturus OA and the
one cycle Nugen amplification and found that the Arctu-
rus method showed the lowest variance and highest corre-
lation[36]. However, our data is distinct in that we
examined the Arcturus Ribo Amp HS kit, which permits
RNA amplification from lower input samples than the
Arcturus OA or Nugen kits. In addition, our study pro-
vides detailed comparisons of amplified RNA to both
total RNA and QPCR, which is not available in the study
by Caretti et al. Wilhelm et al compared Arcturus Ribo
Amp (a less sensitive kit than Ribo Amp HS) to SMART
PCR (Clontech) and concluded that SMART is preferable
when working with less than 200 ng of total RNA[37].
Our study is distinct in that we show that IVT based ampli-
Table 6: Statistical analysis of unfiltered gene set (17,001 genes)
Baugh
500 pg
Baugh
1 ng
Baugh
10 ng
Arcturus
250 pg
Arcturus
500 pg
Arcturus
1 ng
BalPCR
0.667 ng
BalPCR
 3.33 ng
True 
Positives
3072 2454 2786 3366 3306 3297 2816 3373
False 
Positives
2801 1785 1976 3373 3716 3598 3202 4219
True 
Negatives
7448 8465 7882 6875 6190 6621 7047 6031
False 
Negatives
3679 4297 3818 3385 3276 3445 3934 3378
Sensitivity 45.5% 36.4% 42.2% 49.9% 50.2% 48.9% 41.7% 50.0%
Specificity 72.7% 82.6% 80.0% 67.1% 62.5% 64.8% 68.8% 58.8%
Blanks 0 0 5 3 90 5 1 3 4 000
Total 17000 17001 17001 16999 17001 17001 16999 17001
% Correct 61.9% 64.2% 62.7% 60.2% 55.9% 58.3% 58.0% 55.3%
Table 7: Rate of false expression microarray results based on 
QPCR gold standard by amplification technique
Method Quantitiy of Input # False % FER
Modified T7 500 pg 5 13.5
500 pg 5 13.5
500 pg 6 19
1 ng 6 19
1 ng 5 13.5
Mean 5.4 14.6
Arcturus 250 pg 6 19
250 pg 6 19
500 pg 4 10.8
1 ng 4 10.8
Mean 5 13.5
Balanced PCR 500 pg 1 2.7
667 pg 5 13.5
667 pg 4 10.8
3.3 ng 5 13.5
3.3 ng 6 19
Mean 4.2 11.3BMC Genomics 2009, 10:326 http://www.biomedcentral.com/1471-2164/10/326
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fication (Ribo Amp HS) is more reliable than PCR based
amplification at the sub-nanogram input level. Clontech's
SMART PCR is marketed for use at the nanogram low-
input range, not the sub-nanogram range, which is why
we did not include SMART PCR in our comparison.
Shearstone et al performed a comparison of their labora-
tory's novel IVT amplification, termed BIIB, to Arturus
Ribo Amp HS, Nugen Ovation, Affymetrix One and
Affymetrix Two Cycle[38]. Their method, BIIB, proved to
be capable of successful amplification with good repro-
ducibility from 50 pg of total RNA, and could amplify
from lower input amounts of RNA than commercially
available kits. They emphasized that T7 based linear
amplification has advantages over PCR based amplifica-
tion because T7 accurately retains the transcript stoichi-
ometry of the original sample. Our study is similar to that
of Shearstone et al in the design by which they use a refer-
ence RNA for the baseline from which to determine which
of several amplification techniques performs the best at
low inputs of RNA. Our study is distinct in that we found
that Arcturus Ribo Amp HS had acceptable correlation
coefficients in the 250 pg range when attention was
focused to the high intensity spots for data analysis. Our
study provides additional insight on the impact of data
processing on microarray results at low input of total
RNA, which was not the focus of Shearstone et al.
Although BIIB performed well in their hands, Arcturus
Ribo Amp HS is currently commercially available, kit
based, and takes less time to perform than BIIB. Further
studies are needed to compare these two methods and
perhaps improve upon them with the ultimate goal being
consistent successful amplification from even a single cell.
Our paper describes a platform independent measure, the
FER, useful in comparing amplification methods based on
QPCR versus microarray. FER was calculated based on
QPCR of total RNA rather than amplified RNA, since there
was not sufficient amplified product available for per-
forming QPCR on all 37 primer probe pairs. In addition,
QPCR of amplified RNA is biased towards recapitulating
the results of the microarray experiment due to truncation
of the RNA products.
Each of the three amplification techniques yielded fairly
consistent expression results within the constraints of
each technique's input threshold of total RNA, both on
microarray analysis and when compared to QPCR. Based
on these excellent correlations, it is feasible to reproduci-
bly perform high fidelity amplifications by a variety of
techniques when starting with sub-nanogram input quan-
tities of total RNA. However, when attempting expression
arrays analysis from less than 500 pg input, linear ampli-
fication with Arcturus RiboAmp HS was more successful
than the other methods studied.
Below 1 ng, the modified T7 method could not reproduc-
ibly amplify such that insufficient RNA was typically gen-
erated for even a single microarray hybridization. Only by
performing multiple attempts at amplification were we
able to achieve successful amplified product with this
technique. While we were successful in hybridizing 3
arrays with this method at 500 pg we do not recommend
this method below 1 ng of input total RNA as several oper-
ators quite experienced with this method could not repeat
these results. One drawback of this technique is the
greater length of time involved (3 days) compared to
other amplification reactions (2 days) and the relative
complexity of the protocol.
Arcturus RiboAmp HS was able to provide expression
array data at a lower input concentration than any of the
other tested methods and we were able to use smaller
amounts than the manufacturer's recommended mini-
mum sample input of 500 pg total RNA. Below 250 pg,
this method typically failed to amplify in our hands
(although the manufacturer validated the Arcturus
method to a threshold of 100 picograms). This likely rep-
resents a theoretical limit of 25 cells total RNA content
(for laser capture microdissection more would be required
because of fractionation of cellular material), unless spe-
cialized tissues that bear more RNA such as oocytes[35]
are examined. Since each somatic mammalian cell is
thought to have approximately 10 pg of total RNA, the
Arcturus method is especially promising for limiting clin-
ical samples, suggesting that clinical samples comprised
of approximately 25 cells could be routinely analyzed
with Arcturus, or 100 cells with modified T7 or balanced
PCR, with profound implications for correlative science
studies using gene expression profiling that have previ-
ously not considered using such small quantities. It is
somewhat concerning, however, that the % FER was
observed to increase from 10.8% at 500 pg to 19% at 250
pg in our study. This is a potential area of future investiga-
tion as scientists seek to push the lower limit of input RNA
required
Balanced PCR is a promising technique for the amplifica-
tion of low-input quantities of RNA. It maintains a high
degree of accuracy with an input as low as 667 pg of RNA
(FER 10.8–13.5%). While theoretical concern exists
regarding the accuracy of logarithmic amplification meth-
ods, this method overcomes the potential problem by
stopping the PCR reaction before the logarithmic phase of
the PCR curve. This method had the lowest cost per reac-
tion and also required the least amount of technician time
compared to the other methods. In addition, it has been
recently demonstrated that the same balanced-PCR proto-
col used for cDNA amplification may also be used for the
unbiased amplification of whole genomic DNA followed
by array-CGH analysis[21]. However, several iterationsBMC Genomics 2009, 10:326 http://www.biomedcentral.com/1471-2164/10/326
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were required for experienced personnel to learn to suc-
cessfully perform balanced PCR.
These results have certain important limitations to con-
sider. First, hybridizations were carried out sequentially
over a period of several months rather than all at the same
time. It is recognized that arrays that are hybridized
together under identical conditions are more similar to
each other than arrays hybridized on separate occasions.
Additionally, no dye swap experiments were performed.
The rationale for this is that since a standardized universal
reference (StratRef) was employed, it has been demon-
strated that this mitigates the effect of potential experi-
mental bias introduced by separate hybridization
reactions and even permits the comparisons of array data
between members of the research community[15]. Use of
a universal reference may in some cases have advantages
over dye swap experiments. [15]
Each laboratory will have to weigh their decision on
which amplification technique is most suitable based on
factors including amount of starting input total RNA, cost
per reaction, technician time, and experience/comfort
level with the techniques. Laboratories that routinely
work with samples in excess of 1 ng starting material
should focus on cost-savings as each of the methods tested
proved to be reliable above this threshold. Balanced PCR
could be further optimized to include amino-allyl-dUTP
incorporation in the PCR reaction. This would facilitate
indirect Cy dye labeling, which would reduce the labeling
cost for this method.
It is important to ascertain the linearity of a chosen
method at the low input range before going on to work
with precious clinical specimens. Each of the 3 tested
methods performed surprisingly accurately when amplify-
ing from low inputs of total RNA based on microarray
analysis validated with QPCR of 37 genes.
Conclusion
We have demonstrated that it is feasible to reliably and
accurately perform expression profiling from sub-nano-
gram quantities of total RNA. These methods will likely
enable exciting new directions for molecular analysis of
samples previously considered to be of insufficient quan-
tity of total RNA for expression profiling. The data
processing and filtration of microarray results is of funda-
mental importance when attempting analysis of amplifi-
cation reactions from sub-nanogram input amounts of
total RNA.
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